Repligen | RGEN - Ebitda


Repligen reported $43.84M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Agilent USD 577M 77M Jun/2026
Align Technology USD 232.86M 3.72M Jun/2026
Bio Techne USD 115.94M 763K Jun/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Bruker USD 143.2M 33.2M Jun/2026
Charles River Laboratories USD 272.95M 43.14M Jun/2026
Danaher USD 2.1B 257M Sep/2026
Dentsply International USD 190M 61M Jun/2026
General Electric Aerospace USD 3.32B 265M Sep/2026
Henry Schein USD 288M 1000K Jun/2026
Illumina USD 330M 80M Jun/2026
IQVIA Holdings USD 1.03B 38M Sep/2026
Mettler Toledo International USD 322.64M 43.66M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Pfizer USD 6.01B 18M Jun/2026
Repligen USD 43.84M 70K Sep/2026
Revvity USD 228.18M 44.73M Jun/2026
Standard Biotools USD -8.01M 7.8M Mar/2026
Thermo Fisher Scientific USD 3.79B 244M Sep/2026
Waters USD 712M 545M Jun/2026
West Pharmaceutical Services USD 267.4M 23.8M Sep/2026